Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

NDA FilingFenebrutinibPositive

AI Analysis

Summary

Genentech's fenebrutinib became the first BTK inhibitor to receive FDA filing acceptance for both relapsing and primary progressive multiple sclerosis, representing a significant regulatory milestone for the company's neuroinflammation program.

Outcome Details

FDA filing acceptance for BTK inhibitor in both relapsing and primary progressive multiple sclerosis

Importance:7/10

Sentiment:

0.70

FDA FilingBTK InhibitorMultiple SclerosisFirst-in-classRegulatory

Related Companies

$RHHBY

Read the original article

Published by yahoo_finance on September 30, 2026 5:00 AM

Read Original